SGMS1 and glioma: Major progress in the therapy of glioma was achieved with synthetic 2-hydroxyoleic acid (2-OHOA), which proved to be a highly specific activator of the SGMS1 isoform with a significantly higher bioavailability and lower toxicity compared to TMZ when administered in therapeutic doses (Lopez et al., 2023).